An analysis by consumer website GoodRx concluded that the price people pay for generic drugs at the pharmacy varies greatly based on where they live.
An analysis by consumer website GoodRx concluded that the price people pay for generic drugs at the pharmacy varies greatly based on where they live. The study looked at 500 commonly used drugs in 30 of the most populated American cities over the last 12 months, ending April 2018. Researchers examined the average cash price of the drug at a pharmacy. Although many people have insurance coverage for prescriptions or discounts and don’t pay cash, more people are paying larger shares for prescriptions out of pocket. The results are based on a representative sample of US prescription fills (not fills using GoodRx) and comes from several sources including pharmacies and insurers.
The most expensive cities in the country for drugs were New York City (20% more than the national average) and Los Angeles and San Francisco (12.6% and 9.8% higher, respectively). Notably, prices in similar cities in the same state varied widely; in Columbus, Ohio, for example, prices were nearly 22% below the national average. Conversely, Cleveland’s prices were 2.5% above the national average and the 2 cities are only 150 miles apart. The cities with the least expensive drugs are Columbus, Ohio; Atlanta, Georgia (18.6% below); and Houston, Texas (17.4% below).
“This data highlights the nonsensical and variable nature of drug pricing,” the report notes. Cost-of-living differences don’t explain the full story because, for instance, drug prices in Washington, DC, where the cost of living is relatively high, are 9.0% lower than the national average. Raleigh, North Carolina, which has a lower cost of living, has higher prescription drug costs (4.3% higher than the national average).
What GoodRx calls the “Big Box Effect” may play a part in drug price variability because many larger big box stores offer popular brand and generic drugs at a cheaper rate, often $4 for a 30-day supply and $9 for a 90-day supply. Some states have more big box stores, giving residents more opportunities to save on medications.
Retail markup also plays a role in generic drug price disparities because some pharmacies claim a higher margin to support their business and these pharmacies are distributed unevenly throughout a state.
An example of the price differences for the same generic drug across the country are reflected in the comparison of prices for metformin, which treats type 2 diabetes, and the flu medication Tamiflu:
Metformin
Birmingham: $43.00
Boston: $28.57
Columbus: $11.16
New York: $66.23
San Francisco: $49.36
Tamiflu
Birmingham: $197.48
Boston: $185.46
Columbus: $189.61
New York: $155.46
San Francisco: $201.61
While many factors contribute to the differences in generic drug prices, much can still be “chalked up to the ‘drug prices make no sense’ theory,” said Thomas Goetz, GoodRx’s chief of research. Leigh Purvis, AARP's public policy institute director, noted that price variations are not just from city to city, even pharmacies on the same block can sell drugs at very different prices.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.